|  | | |
| |
|
Biogen Idec
|
| |
| |
|
Scientific excellence that achieves new standards of care drives the company's work. Over 20 products are currently in clinical development addressing a variety of key medical needs. In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale. The company is one of a handful of biotechnology companies that has three licensed and dedicated biological bulk-manufacturing facilities, including its large-scale manufacturing plant in Research Triangle Park, NC, which is one of the world's largest cell culture facilities. An additional large-scale manufacturing plant is under construction in Hillerød, Denmark. Biogen Idec has sufficient commercial manufacturing capacity for its own pipeline, as well as potential partners' products. Biogen Idec is headquartered in Cambridge, MA and was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc., founded in 1978, and IDEC Pharmaceuticals Corporation, founded in 1985.
The company maintains research centers of excellence in San Diego, CA and Cambridge, MA. Biogen Idec has additional offices in Canada, Australia, Japan and throughout Europe, including international headquarters in Zug, Switzerland and operates a global distribution network, which covers over 70 countries. The company currently employs approximately 3,900 people worldwide.
|
|
|
|
| |
| |
|
Genentech
|
| |
| |
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions, more than 100 projects in the pipeline and a long term plan for growth.
Genentech's mission is to be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Genentech is committed to high standards of integrity in contributing to the best interests of patients, the medical profession, employees and communities, and to seeking significant returns to the stockholders, based on the continual pursuit of scientific and operational excellence.
Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a fateful meeting in 1976, the two decided to start the first biotechnology company, Genentech.
|
|
|
|
| |
| |
|
GGA Software Services LLC
|
| |
| |
|
For the past 15 years, GGA Software Services LLC has offered world-class outsourced scientific informatics services to major pharmaceutical companies as well as early-stage life science firms. With its headquarters in Cambridge, Massachusetts, and its 350-person development facility in St. Petersburg, Russia, GGA provides superior software engineering, algorithm development, and data curation services, especially in the areas of bioinformatics and cheminformatics. GGA’s professionals combine deep scientific domain expertise and software engineering excellence for the effective design, implementation, and management of scientific informatics projects, as well as support, maintenance, and quality assurance services, at competitive rates. Please visit www.ggasoftware.com.
|
|
| |
| |
|
|
